Open AccessBleomycin in Hodgkin's lymphoma – A boon or a bane? – A retrospective study of bleomycin pulmonary toxicity in Hodgkin's lymphoma
Author(s) -
Chethana Babu K. Udupa,
Prakashini Koteshwar,
Karthik S Udupa
Publication year - 2019
Publication title -
indian journal of palliative care/indian journal of palliative care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 26
eISSN - 1998-3735
pISSN - 0973-1075
DOI - 10.4103/ijpc.ijpc_107_19
Subject(s) - bleomycin , medicine , procarbazine , pulmonary toxicity , dacarbazine , vinblastine , regimen , abvd , vincristine , gastroenterology , lymphoma , surgery , toxicity , cyclophosphamide , chemotherapy
Hodgkin's lymphoma (HL) is one of the most curable malignancies with cure rates of above 85% across all stages. Bleomycin containing regimen is routinely employed in the treatment of HL. Pulmonary toxicity due to this drug is the most feared side effect in these regimens where the mortality rate is approximately 2%-3%. We have conducted this study to assess the genetic susceptibility among the Indian HL patients to bleomycin pulmonary toxicity (BPT).